Leader in the chemical-pharmaceutical industry

CHEMI S.p.A. is a company driven by people dedicated to advancing health for all through cutting-edge research, technological innovation, and unwavering passion.

Expertise in APIs and Complex Molecules

We specialize in the development of generic pharmaceutical principles (APIs) and complex molecules across various therapeutic areas: oncology, cardiovascular, central nervous system, endocrinology, and gastrointestinal.

PRODUCTS

Branded Unique nutraceutical ingredients for our partners

We produce and market branded ingredients for nutraceutical supplements and beverages. 100% of these ingredients are produced in our facilities in Italy and Brazil.

FIND OUT MORE

Chemical-pharmaceutical industry

APIs and complex molecules

Nutraceutical ingredients

Chemi S.p.A. is an Italian company founded in 1973 with a distinctive leadership based on research, production, and commercialization. It has been developing and manufacturing high-value APIs for over 50 years and is renowned as one of the most experienced and long-standing suppliers across the chemical and pharmaceutical industries.

Chemi SpA is part of Italfarmaco Group since 1984 and is specialized in the development, manufacturing and commercialization of:

Competence and innovation are the pillars of our success.
We undertake highly-sophisticated projects in collaboration with our partners to address therapeutic areas with unmet clinical needs.

Our company can rely on people rooted with a deep-history in our organization, contributing to the consistency, continuity and knowledge that bring value to our customers. At the same time, we continuously invest in new generations of talent.

Our History

1973 - Foundation

The first facility is established in Patrica (Frosinone).

1984 - Italfarmaco Acquisition

Chemi becomes a subsidiary of Italfarmaco, engaging in the production and commercialization of raw materials and proprietary active ingredients.

1996 - Peptides and Phospholipids Production

CHEMI expands into the Peptides sector, adding another advanced production technology to its capabilities.
In addition, the technological platform for phospholipids achieves large-scale industrial production.

2000 - Acquisition of ITF Chemical Ltda

Chemi acquires a chemical production facility located in Camaçari, Brazil, further extending its global footprint.

2018 - Givinostat first industrial validation

Givinostat is the first nonsteroidal drug approved for treating DMD (Duchenne muscular dystrophy, providing an alternative to corticosteroids, effective across all genetic variants of DMD.

2024 - DUVYZAT™ (Givinostat) FDA approval

Givinostat, marketed under the brand name Duvyzat, receives FDA approval in March 2024.

OUR MISSION

“Shaping tomorrow by studying today, learning from the past.”

Every achievement stems from our extensive experience and a distinctive approach, grounded in principles and behaviors that set us apart.

Driving Growth with Passion and Innovation

Our values are clear and steadfast, upheld with consistency, courage, and determination. We are always ready to take on new projects, including the most challenging and technologically advanced ones.